Evidence map›Paper›PMID 29939287›Full record

ArticleNucleic acids research2018

EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.

Roberto Paredes, Marion Schneider, Adam Stevens, Daniel J White, Andrew J K Williamson, Joanne Muter, Stella Pearson, James R Kelly, Kathleen Connors, Daniel H Wiseman and 13 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

Roberto ParedesStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Marion SchneiderStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Adam StevensManchester Academic Health Science Centre, Manchester, UK.
Daniel J WhiteStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Andrew J K WilliamsonStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Joanne MuterStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Stella PearsonStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
James R KellyStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Kathleen ConnorsStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Daniel H WisemanManchester Academic Health Science Centre, Manchester, UK.
John A ChadwickManchester Academic Health Science Centre, Manchester, UK.
Harald LöfflerClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Hsiang Ying TengStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Simon LovellManchester Academic Health Science Centre, Manchester, UK.
Richard UnwinStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Henri J van de VrugtOncogenetics, Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands.
Helen SmithManchester Academic Health Science Centre, Manchester, UK.
Olga KustikovaInstitute of Experimental Hematology, Hannover Medical School; Hannover, Germany.
Axel SchambachInstitute of Experimental Hematology, Hannover Medical School; Hannover, Germany.
Tim C P SomervailleManchester Academic Health Science Centre, Manchester, UK.
Andrew PierceStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Anthony D WhettonStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Stefan MeyerStem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Palatine Road, Manchester M20 3LI, UK.
Manchester Academic Health Science Centre · GBMedizinische Hochschule Hannover · DEAmsterdam UMC Location Vrije Universiteit Amsterdam · NLGerman Cancer Research Center · DE

Funding

Cancer Research UK 19280Medical Research Council MR/M008959/1Medical Research Council MR/N00583X/1
6 · The paper itself

Abstract

The transcriptional regulator EVI1 has an essential role in early hematopoiesis and development. However, aberrantly high expression of EVI1 has potent oncogenic properties and confers poor prognosis and chemo-resistance in leukemia and solid tumors. To investigate to what extent EVI1 function might be regulated by post-translational modifications we carried out mass spectrometry- and antibody-based analyses and uncovered an ATM-mediated double phosphorylation of EVI1 at the carboxy-terminal S858/S860 SQS motif. In the presence of genotoxic stress EVI1-WT (SQS), but not site mutated EVI1-AQA was able to maintain transcriptional patterns and transformation potency, while under standard conditions carboxy-terminal mutation had no effect. Maintenance of hematopoietic progenitor cell clonogenic potential was profoundly impaired with EVI1-AQA compared with EVI1-WT, in particular in the presence of genotoxic stress. Exploring mechanistic events underlying these observations, we showed that after genotoxic stress EVI1-WT, but not EVI1-AQA increased its level of association with its functionally essential interaction partner CtBP1, implying a role for ATM in regulating EVI1 protein interactions via phosphorylation. This aspect of EVI1 regulation is therapeutically relevant, as chemotherapy-induced genotoxicity might detrimentally sustain EVI1 function via stress response mediated phosphorylation, and ATM-inhibition might be of specific targeted benefit in EVI1-overexpressing malignancies.

Indexed as

Gene Expression Regulation, LeukemicAcute DiseaseAlcohol OxidoreductasesAnimalsAtaxia Telangiectasia Mutated ProteinsCell LineCell Line, TumorCell Self RenewalDNA-Binding ProteinsGene Expression ProfilingHEK293 CellsHumansLeukemia, MyeloidMDS1 and EVI1 Complex Locus ProteinMutationPhosphorylationAlcohol OxidoreductasesAtaxia Telangiectasia Mutated ProteinsATM protein, humanC-terminal binding proteinDNA-Binding ProteinsMDS1 and EVI1 Complex Locus ProteinMECOM protein, human

Identifiers

PMID29939287
PMCPMC6125627
OpenAlexW2805409869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.